SCHEMBL20239265

SCHEMBL20239265

CNS(=O)(=O)CCc1ccc(Oc2cc(CNc3ncc(Cl)cn3)ccn2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT2 Q96PD7 1/20 0.42
VNN1 O95497 3/20 0.36
CYP3A4 P08684 1/20 0.35
LOXL2 Q9Y4K0 6/20 0.35
LOX P28300 4/20 0.34
PTGES2 Q9H7Z7 2/20 0.34
CYP2C9 P11712 1/20 0.34
CLK1 P49759 2/20 0.33
CLK2 P49760 2/20 0.33
DYRK1A Q13627 2/20 0.33
CLK4 Q9HAZ1 2/20 0.33
DYRK1B Q9Y463 2/20 0.33
HDAC3 O15379 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
ALDH1A1 P00352 1/20 0.33
RAB9A P51151 1/20 0.33
MMP1 P03956 1/20 0.33
MMP13 P45452 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20239243 0.84 DGAT2 (0.42) DGAT2VNN1CYP3A4LOXL2LOX
SCHEMBL20239191 0.82 LOXL2 (0.44) DGAT2VNN1LOXL2LOXHDAC3
SCHEMBL20239324 0.80 VNN1 (0.41) DGAT2VNN1LOXL2LOXCLK1
SCHEMBL20239198 0.80 DGAT2 (0.37) DGAT2VNN1LOXL2LOXCLK1
SCHEMBL18249766 0.79 PLAAT3 (0.44) VNN1LOXL2LOXHDAC3HDAC1
SCHEMBL20239332 0.78 MET (0.38) DGAT2VNN1HDAC3HDAC1HDAC2
SCHEMBL20259233 0.78 LOX (0.45) VNN1CYP3A4LOXL2LOXCYP2C9
SCHEMBL20239161 0.77 DGAT2 (0.36) DGAT2VNN1LOXL2LOXCLK1
SCHEMBL20239285 0.77 VNN1 (0.38) DGAT2VNN1LOXL2HDAC3HDAC1
SCHEMBL20239188 0.77 DGAT2 (0.40) DGAT2VNN1LOXL2LOXCLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107635975-B DGAT2 inhibitors 伊莱利利公司 2020-07-24 CN disclosed
EP-3298001-B1 DGAT2 INHIBITORS LILLY CO ELI (US) 2020-05-13 EP disclosed
US-10053429-B2 DGAT2 inhibitors ELI LILLY AND COMPANY (US) 2018-08-21 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162825-A1 NOVEL DGAT2 INHIBITORS DGAT2, DGAT1, LCAT DGAT2 1/4885VNN1 3148/4885CYP3A4 3118/4885
US-10053429-B2 DGAT2 inhibitors DGAT2, DGAT1, LCAT DGAT2 1/4885VNN1 3615/4885CYP3A4 2675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.